Redpin Therapeutics

Redpin Therapeutics is a privately held, preclinical-stage gene therapy company based in New York City. They are developing a proprietary chemogenetics platform for targeted cell therapies to address currently difficult-to-treat neurological disorders. Their approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmaceutical treatments.